Dopamine agonists for idiopathic hyperprolactinaemia and prolactinoma in adults
نویسندگان
چکیده
منابع مشابه
Hyperprolactinaemia and Prolactinoma
Pregnancy. Puerperium. Breast stimulation. Stress physical (including excessive exercise) or psychological including venepuncture. Macroprolactinaemia: This refers to prolactin of high molecular mass, mostly complexes of monomeric prolactin with immunoglobulins (prolactin autoantibody complexes). These larger molecules have low bioactivity and a prolonged clearance rate similar to that of immun...
متن کاملA case of a prolactinoma resistant to dopamine agonists.
Dopamine agonists are the drugs of choice in the treatment of prolactinomas, the most common type of pituitary adenomas. However, up to 25% of prolactinomas do not respond to these drugs and alternative treatments have to be considered. We describe a 37-year old female with a microprolactinoma who, although having received all available formulations of dopamine agonists over a period of 11 year...
متن کاملCraniopharyngioma with hyperprolactinaemia due to a prolactinoma.
A case is presented in which a histologically proven prolactin secreting pituitary macroadenoma was associated with a large suprasellar craniopharyngioma. The pre-operative prolactin concentration was 8180 mU/l. Although hyperprolactinaemia up to 3000 mU/l in patients with a craniopharyngioma is usually due to stalk compression, greater values may indicate an associated prolactinoma.
متن کاملResistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels.
OBJECTIVE Dopamine agonists normalize prolactin (PRL) levels and reduce tumour size in responsive prolactinoma. However, several cases have shown resistance to dopamine agonists upon initial treatment. Infrequently, prolactinoma initially responds, but then becomes refractory to prolonged treatment (secondary resistance). We investigated the possible mechanisms of resistance to dopamine agonist...
متن کاملDopamine Agonists
Dopamine agonists (DA) have been used to treat symptoms of Parkinson’s disease (PD) since the late 1970s (1). These agents were initially introduced to supplement the beneficial effect and possibly reduce the incidence of longterm complications of levodopa. In the last 30 years, methodical investigations of DA have demonstrated therapeutic benefit in all stages of PD both in combination with le...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cochrane Database of Systematic Reviews
سال: 2018
ISSN: 1465-1858
DOI: 10.1002/14651858.cd009718.pub2